Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal.
OBJECTIVE
To examine the short-term effects of a lipase inhibitor (Orlistat) on physiological and behavioural measures of appetite in response to a high-fat meal.


METHODS
Randomised, single blind, placebo-controlled, crossover trial.


METHODS
A total of 19 healthy nonobese male subjects.


METHODS
After an overnight fast, subjects ingested a test meal of 2940 kJ (60% fat, 30% CHO, 10% protein) with Orlistat (120 mg) or a placebo, separated by 2 weeks. Appetite, as assessed by a standard line scale, and plasma cholecystokinin (CCK) concentrations were measured prior to and every hour after the test meal for 4 h. Thereafter, subjects ingested a quantified, but self-selected portion of a standardised lunch (15% protein, 37% fat and 45% CHO), before completing a final line scale questionnaire.


RESULTS
The CCK response to the test meal was negatively correlated with BMI in both the Orlistat and placebo trials (R=-0.69 and -0.65, P<0.01). Orlistat administration did not significantly alter the CCK response to the test meal (6.30+/-3.27 vs 7.36+/-3.94 pM min, for Orlistat and placebo, P=0.193). Similarly, the line scale measures of appetite and subsequent intake (520+/-205 vs 554+/-197 g, P=0.48) were not different between the trials.


CONCLUSIONS
Orlistat administration did not alter short-term physiological or behavioural measures of satiety in response to a high-fat meal in healthy, nonobese subjects. The CCK response to a test meal may be partly determined by BMI.
Goedecke
J H
JH
UCT/MRC Research Unit for Exercise Science and Sports Medicine, Department of Human Biology, University of Cape Town, South Africa. jluiag@sports.uct.ac.za
Barsdorf
M
M
Beglinger
C
C
Levitt
N S
NS
Lambert
E V
EV
D000328:Adult; D019440:Anti-Obesity Agents / Q000494:pharmacology; D001066:Appetite / Q000187:drug effects*; D002766:Cholecystokinin / Q000097:blood*; D018592:Cross-Over Studies; D004041:Dietary Fats / Q000008:administration & dosage; D004435:Eating / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D006815:Hunger / Q000187:drug effects; D007783:Lactones / Q000009:adverse effects / Q000494:pharmacology*; D008049:Lipase / Q000037:antagonists & inhibitors*; D008297:Male; D000077403:Orlistat; D012527:Satiation / Q000187:drug effects; D016037:Single-Blind Method
D019440:Anti-Obesity Agents; D004041:Dietary Fats; D004791:Enzyme Inhibitors; D007783:Lactones; D002766:Cholecystokinin; D000077403:Orlistat; D008049:Lipase